Creation of a $50m incubation fund focused on early-stage investments in areas of high unmet patient need has been announced by Switzerland-based Helsinn Group.
The privately-owned Swiss firm plans to initially invest directly in 10 to 15 companies, providing scientific and clinical strategy guidance, operational and board support alongside an ongoing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?